5 Cheap Small-Cap Stocks to Buy Before the Next Breakout

3. AbCellera Biologics Inc. (NASDAQ:ABCL)

Number of Hedge Fund Investors In Q2 2023: 25

Latest Share Price: $7.97

AbCellera Biologics Inc. (NASDAQ:ABCL) is a rather unique biotechnology firm that seeks to develop antibodies that are produced by immune systems. The firm reported a hefty $36 million annual revenue drop in its second quarter and its net loss also significantly widened to $30.5 million.

After digging through 910 hedge funds for their second quarter of 2023 shareholdings, Insider Monkey discovered that 25 had held a stake in AbCellera Biologics Inc. (NASDAQ:ABCL). Julian Baker and Felix Baker’s Baker Bros. Advisors is the company’s largest shareholder since it owns $106 million worth of shares.

Follow Abcellera Biologics Inc. (NASDAQ:ABCL)